Vimarsana
Biggest News Aggregation in the World

Anders Edvell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anders Edvell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anders Edvell Today - Breaking & Trending Today

KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma - Vimarsana News

KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma

Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the...

Changes in the board at Isofol Medical AB (publ) - Vimarsana News

Changes in the board at Isofol Medical AB (publ)

Gothenburg, Sweden, June 7, 2023 - Isofol Medical AB announces today that its Board of Directors has appointed Anders Edvell as a co-opted member of the Board. This is following the resignation of... | June 7, 2023

Helsinn and Immedica enter exclusive partnership for - Vimarsana News

Helsinn and Immedica enter exclusive partnership for

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland...

Immedica and OrphanPacific enter agreement giving OrphanPacific rights to Ravicti® (glycerol phenylbutyrate) in Japan - Vimarsana News

Immedica and OrphanPacific enter agreement giving OrphanPacific rights to Ravicti® (glycerol phenylbutyrate) in Japan

Immedica Pharma AB (“Immedica”) and Japanese company OrphanPacific, Inc. (“OrphanPacific”) are happy to announce that they on May 2, 2022, entered an...

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa - Vimarsana News

Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for...